Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2025

Revenue Recognition

Schedule of disaggregation of revenues by payer types

	Three months ended
	March 31,
	2025		2024
	(in thousands)
Insurance carriers	$	472,647	$	341,028
Laboratory partners		20,832		20,276
Patients		8,351		6,437
Total revenues	$	501,830	$	367,741

Schedule of total revenue by geographic area

	Three months ended
	March 31,
	2025		2024
	(in thousands)
United States	$	492,305	$	359,413
Americas, excluding U.S.		1,692		1,481
Europe, Middle East, India, Africa		6,049		5,178
Asia Pacific and Other		1,784		1,669
Total revenues	$	501,830	$	367,741

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at
	March 31,		December 31,
	2025		2024
	(in thousands)
Assets:
Accounts receivable, net	$	318,233	$	314,165
Liabilities:
Deferred revenue, current portion	$	20,557	$	19,754
Deferred revenue, long-term portion (1)		16,705		16,838
Total deferred revenues	$	37,262	$	36,592

(1) The deferred revenue, long-term portion is included within the “Deferred revenue, long-term portion and other liabilities” line item on the consolidated balance sheets.

Schedule of changes in the balance of deferred revenues

	Balance at
	March 31,
	2025			2024
	(in thousands)
Beginning balance	$	36,592	$	35,740
Increase in deferred revenues		10,163		7,941
Revenue recognized during the period included in deferred revenues at the beginning of the period		(9,418)		(7,048)
Revenue recognized from performance obligations satisfied within the same period		(75)		(100)
Ending balance	$	37,262	$	36,533